



Azopt® (brinzolamide) – First-time generic

- On March 8, 2021, [Teva launched](#) an [AB-rated](#) generic version of Novartis' [Azopt \(brinzolamide\)](#) 1% ophthalmic suspension.
- Azopt is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
- Brinzolamide is also available in combination with brimonidine as the brand [Simbrinza®](#) ophthalmic suspension and carries the same indication as Azopt.
- According to IQVIA, Azopt had annual sales of more than \$184 million in the U.S., as of December 2020.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.